Home >> Cyclophosphamide monohydrate
Related Products
Cyclophosphamide monohydrate
alkylating, cytotoxic agent,antitumor activity

Catalog No.A4232
Size Price Stock Qty
10mM (in 1mL DMSO)
$60.00
In stock
50mg
$70.00
In stock
5g
$680.00
In stock
10g
$980.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure

MLN9708

Cyclophosphamide monohydrate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Cyclophosphamide monohydrate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 6055-19-2 SDF Download SDF
Chemical Name N,N-bis(2-chloroethyl)-2-oxo-1,3,2λ5-oxazaphosphinan-2-amine;hydrate
Canonical SMILES C1CNP(=O)(OC1)N(CCCl)CCCl.O
Formula C7H15Cl2N2O2P.H2O M.Wt 279.1
Solubility >14mg/mL in DMSO Storage Store at -20°C
Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

IC50: 511 μM for AChE

Cyclophosphamide monohydrate is used in the cancer treatment in children. As a prodrug it should be metabolized by cytochrome P-450 enzymes to produce the active alkylating species, which are responsible for its cytotoxic effects.

In vitro: Cyclophosphamide inhibited the AChE reversibly with an IC50 of 511 μM. In the control system, Km was 132 μM for AChE, which increased by 78% in the CP treated system. The nature of cyclophosphamide was of the linear mixed type (partially competitive and purely noncompetitive). The values of Ki and KI were estimated to be 378 and 582 μM respectively, indicating that noncompetitive inhibition was predominant over competitive [1].

In vivo: PK studies in mice revealed a delayed plasma clearance of cyclophosphamide after carbon-tetrachloride pretreatment. Plasma levels of total alkylating activity and 4-hydroxycyclophosphamide increased more slowly and reached a lower peak. However, there was no difference in the AUC for either plasma total alkylating activity or plasma 4-hydroxycyclophosphamide between two groups. Thus, prolonged exposure of tumor cells to 4-hydroxycyclophosphamide might be responsible for the increased antitumor activity of cyclophosphamide following carbon-tetrachloride pretreatment [2].

Clinical trial: Twenty-two children not receiving other therapy known to influence drug metabolism were selected, of whom, nine were receiving combination treatment and thirteen were identified as controls. Results showed that the the plasma cyclophosphamide clearance was lower in patients receiving fluconazole combined group [3].

References:
[1] al-Jafari AA,Duhaiman AS,Kamal MA.  Inhibition of human acetylcholinesterase by cyclophosphamide. Toxicology.1995 Jan 19;96(1):1-6.
[2] Harris RN,Basseches PJ,Appel PL,Durski AM,Powis G.  Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study. Cancer Chemother Pharmacol.1984;12(3):167-72.
[3] Yule SM,Walker D,Cole M,McSorley L,Cholerton S,Daly AK,Pearson AD,Boddy AV.  The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos.1999 Mar;27(3):417-21.